CGON: key cretostimogene milestones due by year-end, cash seen lasting to 2029
CGON expects cretostimogene readouts and a planned BLA submission by year-end 2026, with a stated cash runway running through 2029.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
According to TradingView, CGON expects cretostimogene readouts and plans a BLA submission by the end of 2026. These events mark the next major milestones for the company.
The company reports $984.5 million in cash, which it says supports a runway through 2029. Meanwhile, its third-quarter net loss widened to $56.9 million.
why it matters
For investors, the key questions now are the timing and results of the studies and the trend in losses. A large cash cushion reduces the near-term need to raise capital while the main data is still ahead.
market impact
CGON shares: timing of biotech milestones and loss trend shape investor interest
tags
instruments
sources
- CGON: Year-end cretostimogene milestones approach with cash runway projected through 2029 — TradingView, 6 November 2026 at 13:32 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗